Decline in Psychotic Symptoms in Addition to Cardiac and Metabolic Safety with Cariprazine After Poor Response to Previous Antipsychotic Treatments – A Series of Two Cases
Helge HO Müller,1,2 Sebastian Moeller1 1Lehrstuhl für Integrative Psychiatrie und Psychotherapie, Universität Witten/Herdecke gGmbH, Witten, 58448, Germany; 2Gemeinschaftskrankenhaus Herdecke, Abteilung für Psychiatrie und Psychotherapie, Herdecke, GermanyCorrespo...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/17fd112a29384befb7777c2684f485e6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Helge HO Müller,1,2 Sebastian Moeller1 1Lehrstuhl für Integrative Psychiatrie und Psychotherapie, Universität Witten/Herdecke gGmbH, Witten, 58448, Germany; 2Gemeinschaftskrankenhaus Herdecke, Abteilung für Psychiatrie und Psychotherapie, Herdecke, GermanyCorrespondence: Helge HO MüllerLehrstuhl für Integrative Psychiatrie und Psychotherapie, Universität Witten/Herdecke gGmbH, Alfred-Herrhausen-Straße 50, Witten, 58448, GermanyTel +49 2330 62-3167Fax +49 2330 62-3338Email helge.mueller@uni-wh.deAbstract: Cariprazine is a highly effective antipsychotic medication of the latest generation. Due to its special receptor profile with D2/D3 partial agonism and high D3 affinity, the use of cariprazine is particularly justified in negative psychotic symptomatic and cardiac prestressed patients or in patients with weight management problems. In this case series, two cases and the outcomes during the switch to cariprazine treatment under these conditions are described.Keywords: drug-induced, schizophrenia, negative symptoms, side effects, weight, cardiac safety |
|---|